Baird upgraded Vor Bio (VOR) to Outperform from Neutral with a price target of $64, up from $20. The firm said it was impressed by the existing dataset surrounding telitacicept, and to that end notes the large amount of data from RemeGen’s development of telitacicept in China derisks Vor’s ex-China development ambitions. Looking ahead, the firm anticipates investor enthusiasm for telitacicept should continue to build with a pair of late-October data updates in the coming weeks.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio, RemeGen announce Phase 3 study of telitacicept met primary endpoint
- Largest borrow rate increases among liquid names
- Vor Bio files to sell 51M shares of common stock for holders
- Vor Bio upgraded to Buy from Hold at Stifel
- Vor Biopharma’s Strategic Moves and Telitacicept’s Potential Drive Buy Rating Amid Stock Decline